Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/10799
DC FieldValueLanguage
dc.contributor.authorAleksandra Pivkova Veljanovskaen_US
dc.contributor.authorStojanoski, Zlateen_US
dc.contributor.authorLazar Chadievskien_US
dc.contributor.authorIrina Panovska Stavridisen_US
dc.contributor.authorSanja Trajkovaen_US
dc.contributor.authorLidija Cevreskaen_US
dc.contributor.authorBorche Georgievskien_US
dc.date.accessioned2021-03-10T09:48:31Z-
dc.date.available2021-03-10T09:48:31Z-
dc.date.issued2019-05-01-
dc.identifier.citationVeljanovska AP, Stojanoski Z, Chadievski L, Stavridis IP, Trajkova S, Cevreska L, Georgievski B. Posterior Reversible Encephalopathy Syndrome (PRES) in Children Undergoing Allogeneic Stem Cell Transplantation. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2019 May 1;40(1):81-86. doi: 10.2478/prilozi-2019-0007. PMID: 31152638.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12188/10799-
dc.description.abstractPosterior reversible encephalopathy syndrome (PRES) is one of the most serious complication after allogeneic stem cell transplantation in paediatric setting. It is most commonly reported as adverse event of immunosuppressive strategies during transplantation. We present a case of a 7 years old girl with myelodysplastic syndrome (MDS) treated with allogeneic stem cell transplantation (ASCT) at our department. Diagnosis of PRES was confirmed by imaging techniques during the first month after transplant and it was very likely connected with cyclosporine neurotoxicity. The aim of this article is to present our first experience in diagnosing and treating PRES in paediatric stem cell transplantation. Our experience showed that PRES is one of the reasons for higher transplant related mortality in children. Early prediction of factors contributing to PRES and closely monitoring of patient's vital signs, especially blood pressure, neurological status and vision are the main contributors for challenging the patient with another immunosuppressive agent that has less neurological toxicity. Still studies have to be initiated to confirm the influence of PRES on transplant outcome.en_US
dc.language.isoenen_US
dc.publisherMacedonian Academy of Sciences and Arts / Sciendoen_US
dc.relation.ispartofPrilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)en_US
dc.subjectPRESen_US
dc.subjectcomplicationsen_US
dc.subjectcyclosporineen_US
dc.subjectoutcomeen_US
dc.subjectstem cell transplantationen_US
dc.titlePosterior Reversible Encephalopathy Syndrome (PRES) in Children Undergoing Allogeneic Stem Cell Transplantationen_US
dc.typeArticleen_US
dc.identifier.doi10.2478/prilozi-2019-0007-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Journal Articles
Show simple item record

Page view(s)

94
checked on May 3, 2024

Download(s)

18
checked on May 3, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.